Arrhythmias & electrophysiologyCohort study

Defibrillation Testing During Implantation of Subcutaneous Implantable Cardioverter Defibrillators

J Am Coll CardiolPublished

  • Prospective cohort study
  • nationwide
  • observational
  • propensity score-weighted
  • centrally adjudicated endpoints

Defibrillation testing (DT) use decreased from 85.4% (2012-2014) to 66.9% in 2019 (P < 0.001)

Authors' conclusion

Our findings suggest that DT can be safely omitted in the majority of S-ICD recipients, whereas selective DT may be considered in higher-risk subgroups.

Study context

Population
All subcutaneous implantable cardioverter defibrillator (S-ICD) recipients in France (2012–2019)
Participants
4,924 recipients
Exposure
DT omission vs DT during S-ICD implantation
Outcome
Overall mortality, CV mortality, SCD, appropriate and inappropriate shocks by DT status
Follow-up
5 years

Main finding

As reported in the abstract

Nontested vs DTHazard ratio (95% CI)P value
overall mortality
1.17(0.86–1.61)
P = 0.313
CV mortality
1.04(0.70–1.56)
P = 0.846
SCD
0.27(0.04–1.72)
P = 0.167
appropriate shocks
1.01(0.78–1.30)
P = 0.945
inappropriate shocks
0.98(0.78–1.23)
P = 0.865

Observational data: associations, not effects.

Further findings

Independent predictors of DT failure

ComparisonOR (95% CI)P value
Elevated shock impedance (≥89 Ω)4.60 (2.32–9.66)P < 0.001
Obesity (body mass index ≥30 kg/m²)2.17 (1.01–4.55)P = 0.007

Combined ineffective shocks or undetected ventricular arrhythmias

Similar rates (0.05 vs 0.06 per 100 person-years)

Safety

OutcomeValues
DT-related complicationsDT 0.1% · Deaths 2

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Defibrillation Testing During Implantation of Subcutaneous Implantable Cardioverter Defibrillators. J Am Coll Cardiol. Published 8 July 2025. doi:10.1016/j.jacc.2025.04.048

Summarised from the published abstract; every number is checked against it